MA31765B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA31765B1
MA31765B1 MA32755A MA32755A MA31765B1 MA 31765 B1 MA31765 B1 MA 31765B1 MA 32755 A MA32755 A MA 32755A MA 32755 A MA32755 A MA 32755A MA 31765 B1 MA31765 B1 MA 31765B1
Authority
MA
Morocco
Prior art keywords
phenyl
treatment
syndrome
organic compounds
ovaries
Prior art date
Application number
MA32755A
Other languages
Arabic (ar)
English (en)
Inventor
Patrick Chene
Carlos Garcia-Echeverria
Michael Rugaard Jensen
Cornelia Quadt
Thomas Radimerski
Joseph Schoepfer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31765B1 publication Critical patent/MA31765B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention porte sur l'utilisation de l'éthylamide de l'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique ou d'un tautomère de celui-ci ou d'un sel pharmaceutiquement acceptable ou d'un hydrate ou d'un solvate pour le traitement du cancer de la vessie, du côlon, du foie, du poumon, du sein, du vagin, des ovaires, du pancréas, du rein, de l'estomac, du tractus gastro-intestinal, de la prostate, de la tête et du cou, de la cavité péritonéale, de la thyroïde, des os, du cerveau, du système nerveux central et/ou du sang et/ou pour le traitement du syndrome myélodyspiastique, de la mastocytose systémique, du syndrome de von hippel-lindau, de la maladie de castleman multicentrique et/ou du psoriasis.
MA32755A 2007-10-12 2010-04-08 Composes organiques MA31765B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118421 2007-10-12
PCT/EP2008/063605 WO2009047323A2 (fr) 2007-10-12 2008-10-10 Composés organiques

Publications (1)

Publication Number Publication Date
MA31765B1 true MA31765B1 (fr) 2010-10-01

Family

ID=38952098

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32755A MA31765B1 (fr) 2007-10-12 2010-04-08 Composes organiques

Country Status (19)

Country Link
US (6) US20100210650A1 (fr)
EP (3) EP2209529B1 (fr)
JP (2) JP5800504B2 (fr)
KR (4) KR20100075902A (fr)
CN (2) CN101795728A (fr)
AU (1) AU2008309562B2 (fr)
BR (1) BRPI0818559A2 (fr)
CA (1) CA2700795C (fr)
CL (1) CL2008003005A1 (fr)
ES (1) ES2500920T3 (fr)
MA (1) MA31765B1 (fr)
MX (1) MX2010003988A (fr)
PL (1) PL2263751T3 (fr)
PT (1) PT2263751E (fr)
RU (1) RU2491938C2 (fr)
TN (1) TN2010000139A1 (fr)
TW (1) TW200922595A (fr)
WO (1) WO2009047323A2 (fr)
ZA (1) ZA201001546B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017119219A (ru) * 2011-10-14 2018-11-02 Новартис Аг 2-карбоксамид циклоамино производные мочевины в комбинации с ингибиторами hsp90 для лечения пролиферативных заболеваний
BR112015021846A2 (pt) * 2013-03-15 2017-07-18 Novartis Ag biomarcador
US10300026B2 (en) * 2015-08-24 2019-05-28 Shanxi Yabao Health Products Co., Ltd. Use of dihydroxyacetone in preparation of anti-cancer medicaments
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003282512A1 (en) * 2002-10-22 2004-05-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Methods of reducing the activity of and reducing the concentration of a mutant kit protein
KR101166749B1 (ko) 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20070027150A1 (en) * 2005-04-14 2007-02-01 Bellamacina Cornelia R 2-Amino-quinazolin-5-ones
US20070105862A1 (en) * 2005-11-10 2007-05-10 Milan Bruncko Heat-shock protein binders
ES2384906T3 (es) * 2007-03-01 2012-07-13 Novartis Ag Mesilato de etilamida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, hidratos y polimorfos del mismo y formulaciones que comprenden estas formas

Also Published As

Publication number Publication date
BRPI0818559A2 (pt) 2015-04-22
MX2010003988A (es) 2010-04-27
AU2008309562B2 (en) 2012-01-19
JP5800504B2 (ja) 2015-10-28
US20100210650A1 (en) 2010-08-19
US20160045513A1 (en) 2016-02-18
KR20100075902A (ko) 2010-07-05
WO2009047323A2 (fr) 2009-04-16
CA2700795C (fr) 2017-03-07
KR20170124642A (ko) 2017-11-10
EP2263751B1 (fr) 2014-07-09
US20160220576A1 (en) 2016-08-04
EP2263751A1 (fr) 2010-12-22
CN101795728A (zh) 2010-08-04
US20120083496A1 (en) 2012-04-05
CN104306377A (zh) 2015-01-28
JP2011500535A (ja) 2011-01-06
PL2263751T3 (pl) 2014-12-31
KR20160143877A (ko) 2016-12-14
ZA201001546B (en) 2010-10-27
EP2209529B1 (fr) 2018-09-19
TN2010000139A1 (en) 2011-09-26
CL2008003005A1 (es) 2009-05-08
RU2491938C2 (ru) 2013-09-10
US20120214813A1 (en) 2012-08-23
ES2500920T3 (es) 2014-10-01
EP2209529A2 (fr) 2010-07-28
EP3427797A1 (fr) 2019-01-16
RU2010118458A (ru) 2011-11-20
KR101841872B1 (ko) 2018-03-26
AU2008309562A1 (en) 2009-04-16
US20140288075A1 (en) 2014-09-25
KR20160040738A (ko) 2016-04-14
CA2700795A1 (fr) 2009-04-16
JP2014156475A (ja) 2014-08-28
WO2009047323A3 (fr) 2009-11-12
TW200922595A (en) 2009-06-01
PT2263751E (pt) 2014-09-10

Similar Documents

Publication Publication Date Title
MA39628B1 (fr) Procédé de préparation d'amg 416
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
MA49952B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
HRP20120661T1 (hr) Derivati pirimidinil piridazinona
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
WO2019123294A2 (fr) Nouvelles utilisations de dérivés pyrazolo pipéridine
BRPI0511327B8 (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
EP4034530A4 (fr) Inhibiteurs de la protéine kinase i interagissant avec des récepteurs pour le traitement d'une maladie
CN104870431B (zh) 盐形式及晶体形式
MA30704B1 (fr) Compositions therapeutiques
EP2140882A4 (fr) Agent pour le traitement d'une maladie pulmonaire
EP1758854A4 (fr) Composes pyrrolidin-3-yle utiles en tant qu'inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
MA31923B1 (fr) Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes
RU2014141934A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
JP2009541472A5 (fr)
TN2010000139A1 (en) Organic compounds
EP1749532A4 (fr) Médicament pour la guérison ou le traitement d'une blessure
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
JP2019501134A5 (fr)
EA201992685A1 (ru) Раствор леводопы для инфузий
RU2015117550A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, имеющего противораковую активность, с мек ингибитором
EP1815867A4 (fr) Medicament combine pour le traitement d'une maladie auto-immune
RU2017124612A (ru) Комбинация производного 6-оксо-1, 6-дигидро-пиридазона, обладающего противораковой активностью, с ингибитором рэфр